Litcius/Paper detail

Kinase Inhibitors FDA Approved 2018–2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities

Bethany D. Latham, Raeanne M. Geffert, Klarissa D. Jackson

2024Drug Metabolism and Disposition26 citationsDOIOpen Access PDF

Topics & Concepts

PharmacologyDrugMedicineApproved drugTyrosine kinaseKinaseBiologyInternal medicineBiochemistryReceptorQuinazolinone synthesis and applicationsPI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and Mutations
Kinase Inhibitors FDA Approved 2018–2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities | Litcius